Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Johnson & Johnson (JNJ)

JNJ Announces Significant Data From Two Studies Of JNJ-4804 5/5/2026 8:48:48 AM

J&J Reports Positive Phase 3 Results For TREMFYA In Perianal Fistulizing Crohn's Disease 5/5/2026 8:30:24 AM

J&J’s JNJ-4804 Co-Antibody Shows Phase 2b Promise In Refractory IBD, Advancing To Phase 3 Trials 5/5/2026 8:17:57 AM

J&J’s TREMFYA First IL-23 Inhibitor To Show Efficacy In Perianal Fistulizing Crohn’s Disease, Phase 3 FUZION 5/5/2026 8:16:02 AM

Johnson & Johnson Announces Results Of Clinical Study Of OTTAVA Robotic Surgical System 5/5/2026 7:08:39 AM

J & J's Caplyta Shows Better Efficacy Among Adjunctive MDD Treatments In Network Meta-Analysis 5/4/2026 8:40:47 AM

Johnson & Johnson : Study Finds CAPLYTA Favored Vs Atypical Antipsychotics For Add-On MDD Treatment In Adults 5/4/2026 8:09:53 AM

Johnson & Johnson Appoints Ryan Koors As VP, Investor Relations 4/30/2026 8:07:10 AM

Johnson & Johnson: FDA Grants Priority Review For IMAAVY 4/27/2026 8:26:01 AM

Johnson & Johnson: FDA Grants Priority Review To IMAAVY For Warm Autoimmune Hemolytic Anemia 4/27/2026 8:04:46 AM

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia 4/24/2026 10:34:13 AM

Johnson & Johnson's IMAAVY Shows Two Years Of GMG Control 4/24/2026 3:26:42 AM

Johnson & Johnson: New Data Reinforces Efficacy, Sustained Disease Control Of IMAAVY 4/22/2026 8:44:56 AM

Johnson & Johnson’s IMAAVY Demonstrates Sustained Disease Control In Phase 3 GMG Study 4/22/2026 8:12:33 AM

Johnson & Johnson Q1 Earnings Slip Despite Revenue Growth; Lifts Midpoint Revenue Guidance 4/14/2026 8:10:53 AM

Johnson & Johnson Q1 Profit Down, Sales Rise; Lifts FY26 Outlook 4/14/2026 7:43:59 AM

Johnson & Johnson Profit Declines In Q1 4/14/2026 6:33:09 AM

Johnson & Johnson Q1 EPS $2.14; Adj EPS $2.70 4/14/2026 6:23:35 AM

Johnson & Johnson Q1 26 Earnings Conference Call At 8:30 AM ET 4/14/2026 6:03:09 AM

Johnson & Johnson Announces Launch Of VARIPULSE Pro In Europe 4/7/2026 8:33:06 AM

- 1
- 2
- 3
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap